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Blastic plasmacytoid dendritic cell neoplasm usually presents as skin lesions. Diagnostic error occurs when it
primarily presents in leukemic phase without skin involvement. Triad of CD4, CD56 and CD123 immunophe
notype expression is essential to avoid misdiagnosis of this rare hematological malignancy. Here we describe a
patient who presented in overt leukemic phase of BPDCN highlighting diagnostic challenges encountered that
resulted in delayed diagnosis and poor outcome.

1. Introduction
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare,
clinically aggressive hematologic cancer that arises from plasmacytoid
dendritic cells (pDC) [1]. It most commonly manifests as violaceous
bruise-like cutaneous lesions followed by involvement of hema
tolymphoid tissues [2]. Overall, the incidence is extremely low, ac
counting for only 0.44 percent of all hematologic malignancies. Most
patients present in their sixth and seventh decade of life with
well-documented male predominance [3].
In rare instances it primarily presents in acute leukemic phase
involving bone marrow with variable degree of cytopenia. No charac
teristic cytogenetic or molecular abnormality is found in BPDCN and
circulating neoplastic pDC can be easily mistaken for lymphoblast or
myeloblast, therefore, the diagnosis of leukemic phase is heavily
dependent on immunophenotyping [4]. Immunophenotyping shows
characteristic triad of positive expression of C4, CD56, CD123 and
absence of B-cell, T-cell, NK-cells and myeloid lineage specific markers
[4]. Making an early diagnosis without incorporation of immunophe
notyping is therefore challenging. In 2008, World Health Organization
enlisted BPDCN under category of “acute myeloid leukemia and related
precursor neoplasm”, however in 2016, it has been identified as separate
entity [5].
Despite treatment including hematopoietic stem cell transplantation

prognosis is poor, except for isolated skin involvement that tends to do
better. Due to rarity of this disease, there is no agreed-upon standard
treatment. Recently, Tagraxofusp-erzs (the first ever CD123-targeted
agent) has been approved for treatment of BPDCN but is associated
with life-threatening toxicity [6].
Herein, we describe a case of an elderly man who was misdiagnosed
as non-Hodgkin’s lymphoma on initial bone marrow examination and
then as acute leukemia on morphological examination of peripheral
blood smear, before being correctly diagnosed as leukemic BPDCN.
2. Case
A 73-year-old man was referred to our hospital with a four-week
history of generalized weakness, abdominal pain, nausea, and vomit
ing. Physical examination revealed pallor, axillary lymphadenopathy
and splenomegaly. No skin lesions were found. Past medical history was
unremarkable. He has had his bone marrow biopsy done a week earlier,
at the referring hospital which was reported as non-Hodgkin’s lym
phoma and subsequently acute myeloid leukemia was favored on pe
ripheral blood smear morphology. Since there was a discrepancy
between the two reports, the diagnostic workup was re-evaluated at our
facility. A repeat CBC showed Hb: 9.4 g/dl, Hct: 29.7%, Wbc: 12×109/L,
ANC 1.3 × 109/L and platelets 18×109/L. Peripheral blood smear was
leucoerythroblastic with presence of 40% atypical cells closely
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mimicking blast cells (Fig. 1a). Renal function was normal, but liver
function was deranged [total bilirubin 5.5 mg/dl (0.1–1.2), direct bili
rubin 3.8 mg/dl (0–0.2)] with elevated transaminases. Bone marrow
smears, and trephine block were requested to be reviewed by our
hematopathologist which showed aspicular, hemodiluted specimen
exhibiting few atypical cells with eccentric nucleus, fine nuclear chro
matin and weakly basophilic, agranular cytoplasm with pseudopods
(Fig. 1b). Bone trephine showed diffuse infiltration with suppression of
normal haematopoiesis (Fig. 1c).
Based on peripheral blood smear and bone marrow morphological
findings immunophenotyping on peripheral blood was done. Immuno
phenotyping of CD45dim positive cells (35%) within blasts gate (per
formed on BD FACSCanto™ II analyzer, 8 color and 3 lasers) revealed
positivity to CD33 (29%), HLA-DR.. (35%), CD4 (35%), CD7 (32%)
CD123 (35%) and CD56 (35%) but negative for other lineage-specific
markers (like CD19, CD79a, CD22, CD10, cytoplasmic and surface
CD3, CD5, CD8, MPO,CD13, CD14, CD64, CD36, kappa/lambda light
restriction, Tdt,CD34 (Fig. 2& 3).
Extended panel of B-cell markers (CD19, CD22) are negative. T-cell
markers show positive expression of CD4 and CD7.
CT scan showed bilateral axillary and abdominal lymphadenopathy,
splenomegaly and cholelithiasis. Histopathology of axillary lymph node
also exhibited cellular infiltrate with moderate atypical plasmacytoid
cytoplasm and elongated hyperchromatic nuclei, expressing LCA, CD43,
CD4, CD56 with high proliferation index and negative for CD34, CD30,
PAX-5, CD68, CD19, CD20, MPO, CD117, and MUM1. pDC-specific
immunohistochemistry markers were not performed due to nonavailability. Since all lineage specific markers were negative except for
LCA, CD43, CD4 and CD56, and in conjunction with morphology and
immunophenotyping on blood, a diagnosis of BPDCN was made. Cyto
genetics and molecular studies were not sent as it was refused by the
patient. Due to poor performance status, intensive chemotherapy was
deferred and azacytidine along with allopurinol was started. On day 3+
of azacytidine patient’s clinical condition deteriorated and went into
tumor lysis syndrome and acute renal failure. A session of hemodialysis
was performed but patient’s condition was deteriorated, so the level of
care was shifted to palliation after discussion with the family. Conse
quently, the patient died on day 4 of treatment (10th day of hospital
admission).

3. Discussion
The rarity of BPDCN makes it difficult to diagnose amongst hema
tological malignancies, especially when it presents in leukemic phase. In
most cases BPDCN arises de novo and in up to 20% there is a prior
history of myeloid malignancy like myelodysplastic syndrome, chronic
myeloid leukemia, chronic myelomonocytic leukemia, and acute
myeloid leukemia [3].
Approximately 75% of patients, present with isolated skin lesions
followed by lymphadenopathy and splenomegaly and may later progress
to involve other systemic organs [7]. Since skin manifestation is most
common, the diagnosis is usually made on skin biopsy with character
istic histological features. When bone marrow is involved, patient may
present with cytopenia and circulating malignant cells may be detected
in peripheral blood. The malignant cells may exhibit microvacuoles
along the cell membrane giving “pearl necklace" appearance and
pseudopod-like cytoplasmic extensions, however these changes may
sometimes be so subtle that they often get overlooked or be mistaken
with “hand-mirror” appearance of lymphoblasts. However, in most in
stances they mimic poorly differentiated, intermediate-sized blast cells.
Therefore, whenever patient presents in primary leukemic phase
without cutaneous lesions, the diagnosis is often mistaken with acute
leukemia [8].
Hence, the role of immunophenotyping by flowcytometry is crucial
in making a diagnosis as these tumor cells typically express CD43, CD4,
CD56 and one or more markers of PCD like CD123, BDCA-2/CD303,
TCL1 and SBIP [4]. It is important to incorporate PCD markers in
immunophenotype panel specially when most of the lineage specific
markers are negative.
Similarly, it is important to exclude the expression of other lineage
specific markers like lymphoid, myeloid, monocyte before making a
diagnosis of BPDCN [4].
In our case, the patient was misdiagnosed on two occasions, before
presenting to our facility. So, in the best interest of time considering
patient’s clinical condition, immunophenotype was performed on pe
ripheral blood. The immunophenotype displayed a distinct cell popu
lation of abnormal cells. In this case, MPO, CD64, CD14 and CD34 were
negative ruling out the acute myeloid leukemia. CD4 was positive
however negativity of lineage-specific marker CD3 and TdT excluded
the possibility of T-lymphoblastic lymphoma/leukemia. None of the Bcell markers were positive. The possibility of mature plasmacytoid
dendritic cell proliferation was ruled out based on CD56 positive
expression. The tumor cells expressed CD4 and CD56 along with CD123.
At our facility, we rely on expression of CD123 in addition to CD4 and
CD56.
In rare instances CD56 would not be expressed, but still the diagnosis
can be made if there is expression of CD4, CD123 and TCL1. In up to 50%
of the cases TdT and CD68 may be expressed, however the latter is
expressed weakly and shows dot-like positivity in the Golgi zone [9].
Lymph node biopsy was performed to consolidate the diagnosis and to
rule out and differentiate it from other hematological malignancies that
exhibited similar pattern of immunohistochemistry as that of immuno
phenotyping by flowcytometry.
There are several case reports in the literature where diagnosis of
leukemic phase has been mistaken with a wide range of other hemato
logical disorders and patients received unnecessary treatment [10].
Unfortunately, in this case, the patient’s clinical condition was
rapidly deteriorated by the time the diagnosis was confirmed, making
aggressive chemotherapy option undesirable.
The outcome might have been better if the immunophenotyping by
flowcytometry has been incorporated early in the diagnostic workup.
This case consolidates the fact that the diagnosis of leukemic BPDCN
cannot be made in isolation, incorporating clinical presentation with
bone marrow examination and careful evaluation of immunopheno
typing with exclusion of myeloid and lymphoid neoplasm is essential for
timely diagnosis and management.

Fig. 1. Peripheral blood smear showing blast-like cells exhibiting cytoplasmic
pseudopods (100x) (a). Bone marrow aspirate (40x) showing infiltration with
atypical cells with eccentric nucleus, fine nuclear chromatin and weakly
basophilic, agranular cytoplasm with pseudopods (b). Bone trephine H&E (40x)
showing diffuse infiltration with atypical cells and suppression of normal hae
matopoiesis (c).
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Fig. 2. Screening tube exhibiting negative expression of B, T, myeloid marker and TdT.

Fig. 3. Extended myeloid panel shows positive CD33 and HLA-DR… pCD specific markers, CD56 and CD123 are positive.
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